Drug Eluting Stents Market - Insights

Drug eluting stents are small expandable mesh tube made up of medical-grade stainless steel or cobalt alloy metal, that are inserted into the coronary arteries of patients suffering with atherosclerosis. Stent helps to hold the artery open, to release a drug that prevents blockage in artery and improves blood flow in artery.

Stent are mainly used in the procedures such as coronary angioplasty. Drug eluting stents are used in the treatment of coronary artery disease and coronary angioplasty such as percutaneous coronary interventions (PCI) and others. Drug eluting stents comprises three parts, which includes the stent platform, polymer coating (which holds the drug into the stent), and the drug.

The global drug eluting stents market is estimated to be valued at US$ 2,410.8 million in 2019, and is expected to witness a CAGR of 6.4% during the forecast period (2019–2027).

Figure 1. Global Drug Eluting Stents Market Share (%), By Drug, (2019)

Drug Eluting Stents  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing product approvals are expected to drive the global drug eluting stents market growth over the forecast period

Manufacturers of drug eluting stents are focused on gaining regulatory approval to market their products and fulfill the unmet medical needs in cardiac care. For instance, in September 2018, the U.S. Food and Drug Administration (FDA) approved ‘Eluvia’ Drug-Eluting Vascular Stent System of Boston Scientific, which is used in the treatment of peripheral artery disease. 

Moreover, in February 2018, Medtronic Plc, received the U.S. Food and Drug Administration (FDA) approval for its product ‘Resolute Onyx’, it is a 2.0-mm drug-eluting stent (DES), and is one of the smallest drug eluting stent available in the U.S.

Increasing prevalence of cardiovascular diseases are expected to drive demand for treatment and surgical intervention, which in turn is expected to fuel global drug eluting stents market growth

Increasing prevalence of several cardiovascular disease conditions such as heart attack, abnormal heart rhythms, heart failure, heart valve disease, congenital heart disease, and others affecting the function of the heart is expected to propel the global drug eluting stents market growth. For instance, according to the World Health Organization (WHO) in 2015, around 17.7 million people suffered from cardiovascular diseases globally, of which 7.4 million people suffered from coronary heart disease and 6.7 million were encountered from heart stroke.

Rising incidence in cardiovascular disease is expected to increase demand of drug eluting stents, which is further expected to fuel global drug eluting stents market growth over the forecast period. Moreover, unhealthy dietary habits, lack of exercise, and sedentary lifestyles are the major factors that results in increasing prevalence of cardiovascular disease, which leads in increasing mortality rate. For instance, according to the American Heart Association (AHA) in U.S. 2016, around 801,000 deaths were reported due to cardiovascular diseases and around 92.1 million U.S. adults suffered with some form of cardiovascular diseases. Furthermore according to the same source coronary heart disease leads to 45.1% percent death in the U.S. and around 31% of the global deaths.

Global Drug Eluting Stents Market- Regional Analysis

Regional segmentation of the global drug eluting stents market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the global drug eluting stent market over the forecast period, owing to increasing product launches and product approval and presence of major players in the region. For instance, in January 2013, Abbott received the U.S. Food and Drug Administration (FDA) approval to launch ‘XIENCE Xpedition’ everolimus eluting coronary stent system in U.S.

Moreover, key players such as XTENT, Inc., Boston Scientific Corporation, Biosensors International Group, and others are focused on product development and gaining product approvals from regulatory bodies which is expected to drive the drug eluting stents market growth in North America region.

Furthermore, Asia Pacific is expected to witness significant growth in the global drug eluting stents market over the forecast period, owing to increasing technological advancements and development of new products by key players. For instance, in September 2018, MicroPort Scientific Corporation, a China-based healthcare company developed ‘Firehawk’, a drug-eluting stent that is used for treating patients with coronary artery disease. Firehawk is a new generation Rapamycin target eluting coronary stent system.

Figure 2: Global Drug Eluting Stents Market Share (%), By Region, (2019 & 2027)

Drug Eluting Stents  | Coherent Market Insights

Source: Coherent Market Insights (2019)

Restraints

Major factors restraining the global drug eluting stents market growth include product recall. For instance, in October 2013, U.S. FDA sent recall letter to Medtronic plc, for recalling their product
‘Resolute Integrity’ Zotarolimus-eluting Coronary Stent, due to incorrectly mentioned product diameter 2.25 mm instead of the 3.0mm in compliance chart of the product. Moreover, in November 2017, Boston Scientific initiated a voluntary recall of its 150mm ‘Eluvia’ drug-eluting vascular stent, as well as its 180mm and 200mm ‘Innova’ self-expanding stent system, according to a document filed by the Federal Institute for Drugs and Medical Devices in Germany.

Key players

Key players operating in the global drug eluting stents market include Boston Scientific Corporation, Medtronic, Plc, Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology, Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, Abbott Vascular Inc., AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn Biotechnology Co., Ltd, XTENT, Inc., Cardionovum GmbH, Cordis Corporation, and Kyoto Medical Planning Co., Ltd.

Coronary artery stents are small cylindrical device that helps in improving blood flow through arteries to the heart by reducing the blockages in artery. Stents are usually used in the treatment of coronary angioplasty or percutaneous coronary intervention producers. The drug eluting stents types include bare metal coronary artery stents, coronary artery restenosis, coronary artery stents, coronary revascularization, and others. Coronary artery stents are more beneficial for the patients suffering from coronary artery diseases such as myocardial infarction.

Market Dynamics

Manufacturers are focused on developing and launching new products and receiving product approval from regulatory bodies. For instance, in April 2019, Shanghai-based MicroPort Medical (Group) Co., Ltd. received CE (Conformité Européenne) Mark for ‘Firehawk Liberty’, a new generation rapamycin target eluting coronary stent system.

Furthermore, in May 2017, key players such as Medtronic Plc., launched Resolute Onyx drug-eluting stent that provides physicians with additional 4.5mm and 5mm sizes to treat patients with large coronary anatomies in the U.S. Such product launches and product approvals are expected to boost the global drug eluting stents market growth over the forecast period.

Rising incidence of cardiovascular disease, heart failure, and coronary heart disease cases, owing to increasing prevalence of diabetes, obesity, and high blood pressure globally is expected to fuel global drug eluting stents market growth over the forecast period. For instance, according to the American Heart Association (AHA) 2016, around 15.5 million people ≥20 years of age in the U.S. suffered from coronary heart disease. Moreover, according to the same source, it is estimated that each day, every 42 seconds, an American suffered with Myocardial Infraction.

Moreover, increasing prevalence of cardiac diseases is expected to drive growth of the market over the forecast period. For instance, according to the World Health Organization (WHO), in 2017, globally 17.9 million people had death from cardiovascular diseases such as coronary heart disease, peripheral arterial disease, and others.

Key features of the study:

  • This report provides in-depth analysis of the global drug eluting stents market and provides market size (US$ Mn) and cumulative annual growth rate (CAGR) (%) for the forecast period (2020-2027), considering 2019 as a base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, pipeline products,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global drug eluting stents market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launches, market expansion, and marketing tactics
  • The global drug eluting stents market report caters to various stakeholders in this industry, including investors, product developers, distributors, healthcare companies, research institutes, medical device companies, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision making through the various strategy matrices used in analyzing the global drug eluting stents market

Detailed Segmentation:

  • Drug Eluting Stents Market, By Drug
    • Sirolimus
    • Paclitaxel
    • Zotarolimus
    • Everolimus
    • Biolimus
    • Others
  • Drug Eluting Stents Market, By Coating Type
    • Polymer-based Coatings
    • Polymer-free Coatings
  • Drug Eluting Stents Market, By Application:
    • Coronary Artery Diseases
    • Peripheral Artery Diseases
  • Drug Eluting Stents Market, By End User:
    • Cardiology Centers
    • Ambulatory Surgery Centers (ASCs)
    • Hospitals
  • Drug Eluting Stents Market, By Region
    • North America
      •  By Drug:
        • Sirolimus
        • Paclitaxel
        • Zotarolimus
        • Everolimus
        • Biolimus
        • Others
      • By Coating Type:
        • Polymer-based Coatings
        • Polymer-free Coatings
      • By Application:
        • Coronary Artery Diseases
        • Peripheral Artery Diseases
      • By End User:
        • Cardiology Centers
        • Ambulatory Surgery Centers (ASCs)
        • Hospitals
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug:
        • Sirolimus
        • Paclitaxel
        • Zotarolimus
        • Everolimus
        • Biolimus
        • Others
      • By Coating Type:
        • Polymer-based Coatings
        • Polymer-free Coatings
      • By Application:
        • Coronary Artery Diseases
        • Peripheral Artery Diseases
      • By End User:
        • Cardiology Centers
        • Ambulatory Surgery Centers (ASCs)
        • Hospitals
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug:
        • Sirolimus
        • Paclitaxel
        • Zotarolimus
        • Everolimus
        • Biolimus
        • Others
      • By Coating Type:
        • Polymer-based Coatings
        • Polymer-free Coatings
      • By Application:
        • Coronary Artery Diseases
        • Peripheral Artery Diseases
      • By End User:
        • Cardiology Centers
        • Ambulatory Surgery Centers (ASCs)
        • Hospitals
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug:
        • Sirolimus
        • Paclitaxel
        • Zotarolimus
        • Everolimus
        • Biolimus
        • Others
      • By Coating Type:
        • Polymer-based Coatings
        • Polymer-free Coatings
      • By Application:
        • Coronary Artery Diseases
        • Peripheral Artery Diseases
      • By End User:
        • Cardiology Centers
        • Ambulatory Surgery Centers (ASCs)
        • Hospitals
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Drug:
        • Sirolimus
        • Paclitaxel
        • Zotarolimus
        • Everolimus
        • Biolimus
        • Others
      • By Coating Type:
        • Polymer-based Coatings
        • Polymer-free Coatings
      • By Application:
        • Coronary Artery Diseases
        • Peripheral Artery Diseases
      • By End User:
        • Cardiology Centers
        • Ambulatory Surgery Centers (ASCs)
        • Hospitals
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug:
        • Sirolimus
        • Paclitaxel
        • Zotarolimus
        • Everolimus
        • Biolimus
        • Others
      • By Coating Type:
        • Polymer-based Coatings
        • Polymer-free Coatings
      • By Application:
        • Coronary Artery Diseases
        • Peripheral Artery Diseases
      • By End User:
        • Cardiology Centers
        • Ambulatory Surgery Centers (ASCs)
        • Hospitals
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Boston Scientific Corporation *
      • Company Overview
      • Product Portfolio
      • Market Presence
      • Financial Overview
      • Key Developments
      • Strategies
    • Medtronic, Plc.
    • Abbott Laboratories
    • Biosensors International Group
    • Biotronik
    • Lepu Medical Technology
    • Terumo Medical Corporation
    • Cook Medical
    • Shandong JW Medical Systems
    • Stentys
    • Abbott Vascular Inc.
    • AlviMedica Medical Technologies Inc.
    • Amaranth Medical, Inc.
    • HangZhou HuaAn Biotechnology Co.,Ltd
    • XTENT, Inc.
    • Cardionovum GmbH
    • Cordis Corporation
    • Kyoto Medical Planning Co., Ltd.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug
      • Market Snippet, By Coating Type
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Novel Product Launch/Approval
    • Acquisitions and Partnerships
    • Technological Advancement
    • Regulatory Scenario
    • Reimbursement Scenario
    • Product Recalls
    • PEST Analysis
    • PORTER’s Analysis
    • Epidemiology
  4. Global Drug Eluting Stents Market, By Drug, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Sirolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Paclitaxel
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Zotarolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Everolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Biolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  5. Global Drug Eluting Stents Market, By Coating Type, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Polymer-based Coatings
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Polymer-free Coatings
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  6. Global Drug Eluting Stents Market, By Application, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Coronary Artery Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Peripheral Artery Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  7. Global Drug Eluting Stents Market, By End User, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Cardiology Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Ambulatory Surgery Centers (ASCs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  8. Global Drug Eluting Stents Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Coating Type, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Coating Type, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Coating Type, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Coating Type, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Coating Type, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2016 – 2027 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Drug, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Coating Type, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • Boston Scientific Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Medtronic, Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Biosensors International Group
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Biotronik
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Lepu Medical Technology
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Terumo Medical Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Cook Medical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Shandong JW Medical Systems
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Stentys
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Abbott Vascular Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • AlviMedica Medical Technologies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Amaranth Medical, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • HangZhou HuaAn Biotechnology Co.,Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • XTENT, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Cardionovum GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Cordis Corporation
        • Company Highlights
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
      • Kyoto Medical Planning Co., Ltd.
        • Company Highlights
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategy
    • Analyst Views
  10. Section
    • Research Methodology
    • About us and Services

*Browse 34 market data tables and 27 figures on Drug Eluting Stents Market- Global forecast to 2027”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users